# ZJYL (Jin Medical International Ltd.) - SEC EDGAR Financial Statements

> Jin Medical International Ltd. reported $20.69M in revenue and net income of $1.19M for the fiscal year ended September 30, 2025 (down 12.0% year over year), with a 29.2% gross margin and a 2.9% operating margin.

- Canonical: https://convexityos.com/fundamentals/ZJYL
- Markdown: https://convexityos.com/fundamentals/ZJYL.md
- SEC CIK: 0001837821
- Reporting currency: USD
- Latest filing period: September 30, 2025
- Last synced: Nov 21, 2026, 05:01 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001837821&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $20.69M | -12.0% YoY |
| Operating Income | FY 2025 | $608K | 2.9% margin |
| Net Income | FY 2025 | $1.19M | 5.8% net margin |
| Diluted EPS | FY 2025 | $0.01 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$3.73M | -18.0% FCF margin |
| Cash & ST Investments | Sep 30, 2025 | $29.63M | Total debt: $18.91M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Revenue** | $20.69M | $23.50M | $19.82M | $19.19M | $20.76M |
| Cost of Revenue | $14.64M | $14.00M | $13.04M | $12.99M | $14.40M |
| **Gross Profit** | $6.04M | $9.50M | $6.78M | $6.20M | $6.36M |
| Research & Development | $1.56M | $1.50M | $1.54M | $1.89M | $1.57M |
| Selling, General & Admin | $3.88M | $4.37M | $2.37M | $2.18M | $2.16M |
| Total Operating Expenses | $5.44M | $5.86M | $3.92M | $4.07M | $3.73M |
| **Operating Income** | $608K | $3.64M | $2.87M | $2.13M | $2.63M |
| **EBITDA** | $852K | $3.88M | $3.09M | $2.49M | $2.98M |
| Interest Income | $789K | $467K | $183K | $182K | $64K |
| Income Before Tax | $1.60M | $4.18M | $3.22M | $2.74M | $2.88M |
| Income Tax Expense | $215K | $764K | $344K | $36K | $249K |
| **Net Income** | $1.19M | $3.68M | $2.88M | $2.71M | $2.63M |
| Basic EPS | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 |
| **Diluted EPS** | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 |
| Basic Shares Outstanding | 156.5M | 156.5M | 145.1M | 135.0M | 135.0M |
| Diluted Shares Outstanding | 156.5M | 156.5M | 145.1M | 135.0M | 135.0M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.46M | $8.14M | $6.93M | -- |
| Short-Term Investments | $22.17M | $18.62M | $9.77M | $2.28M |
| **Cash & Short-Term Investments** | $29.63M | $26.76M | $16.70M | -- |
| Accounts Receivable, Net | $5.81M | $5.91M | $3.28M | $3.83M |
| Inventory | $4.92M | $5.17M | $5.05M | $6.72M |
| **Total Current Assets** | $44.14M | $42.82M | $31.12M | $18.90M |
| Property, Plant & Equipment, Net | $7.90M | $1.46M | $1.48M | $1.63M |
| Intangible Assets | $1.10M | $1.15M | $154K | -- |
| **Total Non-Current Assets** | $9.23M | $2.98M | $1.79M | $2.04M |
| **Total Assets** | $53.37M | $45.80M | $32.90M | $20.94M |
| Accounts Payable | $3.26M | $3.01M | $3.39M | $4.11M |
| Short-Term Debt | $18.84M | $11.32M | $4.11M | -- |
| Deferred Revenue (Current) | $495K | $671K | -- | -- |
| **Total Current Liabilities** | $23.80M | $17.15M | $8.92M | $5.70M |
| **Total Non-Current Liabilities** | $0 | $96K | $0 | $0 |
| **Total Liabilities** | $23.80M | $17.25M | $8.92M | $5.70M |
| **Total Debt (incl. Leases)** | $18.91M | $11.60M | $4.11M | -- |
| Common Stock | $7.8K | $7.8K | $7.8K | $6.8K |
| Retained Earnings | $20.94M | $20.02M | $16.93M | $14.41M |
| Accumulated Other Comp. Income | -$924K | -$556K | -$1.40M | -$911K |
| **Total Stockholders' Equity** | $29.64M | $28.82M | $23.98M | $15.24M |
| Total Equity | $29.57M | $28.55M | $23.98M | $15.24M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.46M | $8.14M | $6.93M | -- |
| Short-Term Investments | $22.17M | $18.62M | $9.77M | $2.28M |
| **Cash & Short-Term Investments** | $29.63M | $26.76M | $16.70M | -- |
| Accounts Receivable, Net | $5.81M | $5.91M | $3.28M | $3.83M |
| Inventory | $4.92M | $5.17M | $5.05M | $6.72M |
| **Total Current Assets** | $44.14M | $42.82M | $31.12M | $18.90M |
| Property, Plant & Equipment, Net | $7.90M | $1.46M | $1.48M | $1.63M |
| Intangible Assets | $1.10M | $1.15M | $154K | -- |
| **Total Non-Current Assets** | $9.23M | $2.98M | $1.79M | $2.04M |
| **Total Assets** | $53.37M | $45.80M | $32.90M | $20.94M |
| Accounts Payable | $3.26M | $3.01M | $3.39M | $4.11M |
| Short-Term Debt | $18.84M | $11.32M | $4.11M | -- |
| Deferred Revenue (Current) | $495K | $671K | -- | -- |
| **Total Current Liabilities** | $23.80M | $17.15M | $8.92M | $5.70M |
| **Total Non-Current Liabilities** | $0 | $96K | $0 | $0 |
| **Total Liabilities** | $23.80M | $17.25M | $8.92M | $5.70M |
| **Total Debt (incl. Leases)** | $18.91M | $11.60M | $4.11M | -- |
| Common Stock | $7.8K | $7.8K | $7.8K | $6.8K |
| Retained Earnings | $20.94M | $20.02M | $16.93M | $14.41M |
| Accumulated Other Comp. Income | -$924K | -$556K | -$1.40M | -$911K |
| **Total Stockholders' Equity** | $29.64M | $28.82M | $23.98M | $15.24M |
| Total Equity | $29.57M | $28.55M | $23.98M | $15.24M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | $1.38M | $3.42M | $2.88M | $2.71M | $2.63M |
| Depreciation & Amortization | $243K | $238K | $226K | $363K | $347K |
| Change in Receivables | $1.28M | -$2.39M | $349K | $242K | $159K |
| Change in Inventory | $168K | $80K | $1.56M | -$504K | $459K |
| Change in Payables | $287K | -$500K | -$647K | -$810K | -$369K |
| **Operating Cash Flow** | $2.90M | -$1.21M | $3.11M | $1.58M | $5.84M |
| Capital Expenditure | -$6.63M | -$145K | -$114K | -$40K | -$43K |
| **Free Cash Flow** | -$3.73M | -$1.35M | $2.99M | $1.54M | $5.80M |
| Acquisitions, Net | -$500K | -- | -- | -- | -- |
| **Investing Cash Flow** | -$10.79M | -$9.51M | -$7.73M | -$121K | -$1.07M |
| Common Stock Issued | -- | $312K | -- | -- | -- |
| **Financing Cash Flow** | $7.35M | $11.65M | $6.91M | $122K | -$2.87M |
| **Net Change in Cash** | -$675K | $1.21M | $2.14M | $1.12M | $2.01M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Gross Margin** | 29.2% | 40.4% | 34.2% | 32.3% | 30.6% |
| **Operating Margin** | 2.9% | 15.5% | 14.5% | 11.1% | 12.7% |
| **Net Profit Margin** | 5.8% | 15.6% | 14.5% | 14.1% | 12.7% |
| Return on Equity (ROE) | 4.0% | 12.8% | 12.0% | 17.8% | -- |
| Return on Assets (ROA) | 2.2% | 8.0% | 8.7% | 12.9% | -- |
| Current Ratio | 1.86x | 2.50x | 3.49x | 3.31x | -- |
| Quick Ratio | 1.65x | 2.19x | 2.92x | 2.14x | -- |
| Debt to Equity | 0.64x | 0.40x | 0.17x | -- | -- |
| **Revenue Growth (YoY)** | -12.0% | +18.6% | +3.3% | -7.6% | -- |
| Gross Profit Growth (YoY) | -36.4% | +40.1% | +9.5% | -2.6% | -- |
| Operating Income Growth (YoY) | -83.3% | +26.9% | +34.6% | -19.0% | -- |
| **Net Income Growth (YoY)** | -67.6% | +27.7% | +6.3% | +2.8% | -- |
| EPS Growth (YoY) | -50.0% | 0.0% | 0.0% | 0.0% | -- |
| Operating Cash Flow Growth (YoY) | -- | -138.9% | +96.5% | -72.9% | -- |
| Free Cash Flow Growth (YoY) | -- | -145.2% | +94.3% | -73.4% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
